The Roswell Park Institute of the United States announced the beginning of a clinical study with the Cuban vaccine CIMAvax-EGF in the prevention of lung cancer.
The new trial beginning in the United States seeks to treat smoking patients at high risk of developing lung cancer, as well as early-stage cancer patients at risk of relapse with the disease. The Cuban drug CIMAvax-EGF, an immunotherapy that dramatically reduces the levels of epidermal growth factor (EGF) in the blood, has been shown to be effective in treating advanced lung cancer.
Based on the results obtained in the two countries, researchers from the Center for Molecular Immunology and the Roswell Park Institute, located in New York State, begin to explore its use to prevent the formation of lung cancer.
This would be the second ongoing clinical trial with CIMAvax-EGF in Roswell Park, where the safety of this drug has been demonstrated, and its combined use in various cancer indications is being explored.
Source: CMHW
Views: 0
